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Hyperhomocysteinemia, an independent cardiovascular risk
factor, is present in the majority of hemodialysis patients.
Among the postulated mechanisms of toxicity, protein
homocysteinylation is potentially able to cause significant
alterations in protein function. Protein homocysteinylation
occurs through various mechanisms, among which is the
post-translational acylation of free amino groups
(protein-N-homocysteinylation, mediated by homocysteine
(Hcy) thiolactone). Another type of protein homocysteinylation
occurs through the formation of a covalentSS bond, found
primarily with cysteine residues (protein-S-homocysteinylation).
Scant data are available in the literature regarding the extent to
which alterations in protein homocysteinylation are present in
uremic patients on hemodialysis, and the effects of folate
treatment are not known. Protein homocysteinylation was
measured in a group of hemodialysis patients (n¼ 28)
compared to controls (n¼ 14), with a new method combining
protein reduction, gel filtration and Hcy derivatization. Chemical
hydrolysis was performed, followed by high-pressure liquid
chromatography separation. The effects of folate treatment
on protein homocysteinylation, as well as in vitro
binding characteristics were evaluated. Plasma Hcy,
protein-N-homocysteinylation and protein-S-homocysteinylation
were significantly higher in patients vs controls. Plasma
Hcy and protein-S-homocysteinylation were significantly
correlated. After 2 months of oral folate treatment,
protein-N-homocysteinylation was normalized, and
protein-S-homocysteinylation was significantly reduced. Studies
on albumin-binding capacity after in vitro homocysteinylation
show that homocysteinylated albumin is significantly altered at
the diazepam-binding site. In conclusion, increased protein
homocysteinylation is present in hemodialysis patients, with
possible consequences in terms of protein function. This
alteration can be partially reversed after folate treatment.
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In hemodialysis patients, high plasma homocysteine (Hcy)
levels are commonly present.1,2 Hyperhomocysteinemia has
been linked to increased cardiovascular risk in the general
population, where mild increases in Hcy levels apply.3 In
uremic patients on hemodialysis, high Hcy levels, usually in
the moderate–intermediate range, have been linked to higher
cardiovascular risk and mortality.4
The possible mechanisms through which increased Hcy
levels exert a toxic effect in uremia are as follows: oxidation,
nitrosylation and DNA and protein hypomethylation.5,6
Another potential mechanism of Hcy toxicity is protein
homocysteinylation. Only scant data are available in the
literature on the extent of protein homocysteinylation in
uremic patients.7
In general, protein homocysteinylation, that is, the
binding of Hcy to proteins, can occur in the following ways:
(i) the acylation of free amino groups, termed protein-N-
homocysteinylation, in particular, the binding of Hcy
to the e amino group of lysine residues and the
terminal amino group of proteins (mediated by Hcy
thiolactone, an Hcy derivative,8); and
(ii) oxidation of thiol groups, mediated by Hcy in its free
form, termed protein-S-homocysteinylation (in parti-
cular directed towards cysteine (Cys) residues,9).
In this work, we refer to these two mechanisms as ‘protein
homocysteinylation’ (see Figure 1 for a depiction of the
moieties involved). The introduction of S-nitroso-Hcy
(derived through the nitrosylation of Hcy by NO) in the
covalent backbone of proteins10 is a translational process and
is considered part of the nitrosylation mechanism.
Formation of Hcy thiolactone, involved in protein-N-
homocysteinylation, is a consequence of a proof-reading
reaction that prevents the post-translational incorporation of
Hcy into proteins,11 or it can appear as a result of a reaction
that binds Hcy to initiator methionyl tRNA. This complex is
then methylated to methionine by a methylating factor.
When hypomethylation is present, the Hcy–tRNA complex is
hydrolyzed to form Hcy thiolactone.12
When plasma proteins are incubated in the presence of
Hcy thiolactone, homocysteinylation occurs spontaneously,
that is, through a non-enzymatic reaction, and rapidly, with
the complete disappearance of Hcy thiolactone from the
medium after 3 h.13
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The consequences of increased protein homocysteinyla-
tion are represented by protein damage, monitored by altered
electrophoretic mobility, and loss of enzymatic activity (with
protein denaturation), found in several model systems, such
as plasma proteins, methionyl tRNA synthetase, tripsyn, lysin
oxidase, etc.13 Technical difficulties may be encountered
when determining Hcy thiolactone in the blood, probably
because of the high molecular reactivity. Only recently, a
high-performance liquid chromatography (HPLC) method
has been published for an Hcy thiolactone assay in the
plasma.14 However, when there is an increase in the blood
Hcy, an increase in homocysteinylated proteins can be
observed.15 Lately, it has been demonstrated that N-homo-
cysteinylation affects the susceptibility of albumin to
oxidation and proteolysis,16 thus probably rendering this
protein more prone to be cleared from circulation.
Therefore, protein homocysteinylation could be one of the
mediators of Hcy toxicity, contributing to structural and
functional alterations at the molecular and cellular levels.
The aim of our study was to measure homocysteinylated
proteins in uremic patients on hemodialysis, and to verify
whether folate treatment would affect protein homocystei-
nylation. In addition, the consequences of protein homo-
cysteinylation were investigated in relation to the in vitro
binding properties of modified albumin.
RESULTS
Hcy levels, folate and vitamin B6 and B12 in patients and
controls
Results relative to plasma total, protein-bound and non-
protein-bound Hcy (tHcy) are shown in Table 1. As expected,
tHcy levels were significantly higher in uremics compared to
controls (Po0.001).
The tHcy concentration range in the 28 patients in Table 1
was 14.50–221.34 mM. In uremic patients, folate levels were
13.3 (s.d. 5.4) nmol/l, while the vitamin B6 level was 17.23
(s.d. 4.7) nmol/l and the vitamin B12 level was 475.2 (s.d.
65.5) pmol/l.
Protein-N-Hcy and protein-S-Hcy levels in patients and
controls
Results relative to plasma protein-N-Hcy and protein-S-Hcy
are shown in Table 1.
Protein-N-Hcy, expressed both as mM and as pmol/mg
protein, was significantly different from controls in uremics.
The concentration of Hcy bound to proteins through the
disulfide bridge was also significantly different from control
values, expressed both as mM and pmol/mg protein.
As for the correlations between tHcy levels and protein
homocysteinylation, the results can be found in Table 2. The
Pearson correlation coefficients and linear regression are
relative to tHcy and protein-N-Hcy, and tHcy and protein-
S-Hcy, both in controls and uremics. A significant value can
be found considering the correlation between tHcy and
protein-S-Hcy, both in controls and uremics, basically
underscoring the fact that tHcy is the sum of protein-S-
Hcy, Hcy-Hcy, Hcy-Cys and free Hcy in the blood. Therefore,
in this case, total Hcy reflects the protein-S-Hcy content.
Folate treatment
Results relative to folate treatment are shown in Table 3.
The plasma tHcy concentration range was 16.47–
178.88mM. Plasma tHcy levels were significantly reduced after
treatment, although tHcy levels were still above normal levels.
Before therapy, in uremics, protein-N-Hcy and protein-S-Hcy
were significantly higher with respect to control. After
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Figure 1 | Protein adducts of Hcy with plasma proteins. Protein-
N-homocysteinylated derivatives, with either free N-terminus or the
e-amino group of lysine residues (particularly Lys525 in serum
albumin). Protein S-homocysteinylated derivatives (particularly with
Cys34 in serum albumin). Protein-N-homocysteinylated–S-derivatives
are also possibly formed.16 The shaded area indicates the group,
which is homocysteinylated in proteins.
Table 1 | Mean concentration levels (s.e.) of tHcy, protein-N-Hcy and protein-S-Hcy in controls and uremic patients on
hemodialysis, the latter expressed as lM concentration and as pmol/mg protein
tHcy (lM) Protein-N-Hcy (lM) Protein-N-Hcy (pmol/mg) Protein-S-Hcy (lM) Protein-S-Hcy (pmol/mg)
Controls (n=14) 11.35 (1.03) 0.35 (0.13) 4.65 (2.74) 9.46 (1.20) 139.52 (15.43)
Uremics (n=28) 57.84 (9.92)* 0.68 (0.10)* 12.40 (2.25)* 52.02 (9.16)* 825.53 (121.08)*
*Po0.001 vs control *Po0.05 *Po0.05 *Po0.05 *Po0.001
Protein-N-Hcy, Hcy bound to proteins through the amide bond; protein-S-Hcy, Hcy bound to proteins through the disulfide bridge.
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therapy, protein-N-Hcy levels in uremics were significantly
reduced, compared to before therapy. Protein-N-Hcy, after
therapy, was not significantly different from control values,
both expressed as mM and pmol/mg protein (healthy
individuals shown in Table 1). In the case of protein-S-Hcy,
there was a significant difference after therapy with respect to
levels prior to folate therapy. However, the levels were still
higher than those of control subjects.
Binding of xenobiotics to homocysteinylated albumin
Results relative to experiments with homocysteinylated
albumin compared to control untreated human albumin
are shown in Figure 2. Homocysteinylated albumin binding
to warfarin, and salicylic acid (SA) was not different from
control untreated albumin (Figure 2, panels a and b), whereas
for diazepam, the binding curve showed a significant
difference from that obtained with control albumin
(Po0.0001, Figure 2, panel c). To be more specific, this
pattern indicates that, utilizing a whole gamut of diazepam
concentrations, from very small to large, the treated albumin
binds significantly less diazepam, and is therefore altered in
its binding capacity. In fact, the reduction (quenching) of
albumin fluorescence, induced by binding with diazepam, is
significantly less with respect to control.
DISCUSSION
In this paper, we measured plasma protein homocysteinyla-
tion by a method combining protein reduction, gel filtration,
derivatization and hydrolysis, followed by HPLC separation,
which allows to quantify both protein-N-Hcy and protein-
S-Hcy. The results showed that Hcy bound through both the
disulfide bridge and the amide link was significantly
increased in plasma proteins of end-stage renal disease
patients on hemodialysis. After folate therapy, Hcy bound
through the amide bond reached normal levels, whereas Hcy
bound through the disulfide bridge was reduced, but not
normalized. Binding to albumin, which was homocysteiny-
lated in vitro, of diazepam, a ligand to one of the main
binding sites, was significantly reduced.
First of all, we show that both types of protein
homocysteinylation are increased in plasma proteins of
uremic patients on hemodialysis. This is not particularly
surprising, given the high tHcy levels to which these patients
are chronically subject.
The increase in tHcy levels in hemodialysis patients
involves both the protein-bound and its free reduced form,17
which is in equilibrium with other reactive forms of Hcy (e.g.
S-adenosylhomocysteine, 1, 2). When tHcy levels in the
blood are high, levels of protein-N-Hcy are increased as
well.15 This could be ascribed to higher levels of Hcy
thiolactone in the blood due to its increased production.
Higher Hcy thiolactone levels may also be due to the reduced
activity of Hcy thiolactonase, the enzyme that hydrolyzes Hcy
thiolactone in the blood. Recent reports have shown that
serum paraoxonase activity is reduced in chronic renal failure
patients.18–20 This enzyme is identical to Hcy thiolactonase,21
and its reduced activity has been implicated in cardiovascular
disease. In fact, this enzyme is a component of high-density
lipoprotein, and reduces low-density lipoprotein lipid
peroxidation,22 thus providing an explanation for the
protective role of high-density lipoprotein. It is also possible
that the reduced activity of thiolactonase present in uremia
may lead to increased Hcy thiolactone levels and therefore
high protein homocysteinylation, as shown in this paper,
with consequent implications with respect to atherosclerosis
in this patient population as well.23
Table 2 | Pearson’s correlation coefficients (first line), linear regression (second line) and significance levels of the correlation
between tHcy, protein-N-Hcy and protein-S-Hcy, both in controls and uremics
tHcy+protein-S-Hcy (lM) tHcy+protein-S-Hcy (pmol/g) tHcy+protein-N-Hcy (lM) tHcy+protein-N-Hcy (pmol/g)
Control R=0.8752* R=0.9019* NS NS
R=0.7660* R=0.8134* NS NS
Uremic R=0.6901* R=0.7003* R=0.5506** NS
R=0.4762* R=0.4904* R=0.3032* NS
*Po0.0001, **Po0.0024.
NS, non siginificant.
Table 3 | Mean concentration levels (s.e.) of tHcy, protein-N-Hcy and protein-S-Hcy uremic patients on hemodialysis, the latter
expressed as lM concentration and as pmol/mg protein, before and after folate therapy
tHcy (lM) Protein-N-Hcy (lM) Protein-N-Hcy (pmol/mg) Protein-S-Hcy (lM) Protein-S-Hcy (pmol/mg)
Before therapy (n=15) 69.38 (15.15) 0.86 (0.14) 15.73 (2.95) 67.49 (15.72) 1142.46 (255.92)
After therapy (n=15) 29.13 (4.04) 0.40 (0.06) 7.07 (1.38) 26.01 (3.80) 438.15 (62.02)
After compared to before Po0.025 Po0.025 Po0.05 Po0.02 Po0.01
After therapy vs controls Po0.001 P n.s. P n.s. Po0.001 Po0.001
Protein-N-Hcy, Hcy bound to proteins through the amide bond; protein-S-Hcy, Hcy bound to proteins through the disulfide bridge.
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Both in the patient population and in controls, protein-
S-Hcy was significantly correlated to Hcy levels, whereas
protein-N-Hcy was much less stringently correlated to tHcy,
and only in the patient population. This finding may reflect
the closer ties between tHcy levels and the facile formation of
disulfide bonds in proteins, whereas the formation of the
amide bond, perhaps, is subjected to different variables,
among which is thiolactonase activity, for example.
Notably, other investigators have measured protein-N-Hcy
with different technical approaches. For example, Jakubow-
ski, a pioneer in this field, utilized the chemical conversion of
protein-N-Hcy into Hcy thiolactone and two-dimensional
thin-layer chromatography, followed by HPLC separation on
a cation exchange column with multiwavelength diode array
ultraviolet detection. Therefore, the levels obtained with this
method cannot be easily compared to ours. However, it
appears from data published in Jakubowski8 (Figure 4) and
Jakubowski15 that the average in the controls is somewhat
higher with respect to our data, but still in the same range. In
addition, there is a wide variability, attributed by the author
to paraoxonase activity. In the case of Uji et al.,7 the authors
measured protein-N-Hcy in hemodialysis patients and
controls with a method involving a derivatization reaction
with 4-fluoro-7-sulfamoyl-benzofurazon (ABD-F), followed
by acid hydrolysis, and then HPLC separation and fluores-
cence detection. These authors obtained results that practi-
cally overlapped with ours: the mean in the controls was
0.51 mM, and the mean was 0.74 mM in 15 hemodialysis
patients. The increase of protein-N-Hcy in hemodialysis
patients is about double the value in control patients, whereas
the increase in plasma tHcy levels and that of protein-S-Hcy
are comparable and about five times the values present in
control subjects. This discrepancy could be theoretically
attributable to the interference of processes such as protein
carbamylation. In fact, under conditions of high urea levels in
the blood, such as uremia, urea is spontaneously transformed
into isocianate, which reacts with the terminal amino group
of proteins and with the e-amino group of lysine residues
(carbamylation24). These are the same chemical groups that
Hcy thiolactone reacts with, in the formation of protein-
N-Hcy. Therefore, it is possible that the two compounds
compete in vivo, thus leading to a lower than expected
(considering the plasma tHcy levels) increase in protein-
N-Hcy.
In addition, the levels of protein-N-Hcy in absolute
amounts can be considered to be quite low, when compared
to protein-S-Hcy and plasma tHcy levels (protein-N-Hcy is
4.65 pmol/mg in controls and 139.52 pmol/mg in uremics;
protein-S-Hcy is 12.4 pmol/mg in controls and 825.53 pmol/
mg in uremics). However, it has been recently reported that
an autoimmune response to protein-N-Hcy is present in
stroke patients and early-onset coronary artery disease
patients.25,26 Therefore, protein-N-Hcy, even if present in
small amounts, can be recognized as a neoself antigen, thus
inducing an immune activation, which is an important
modulator of atherogenesis.
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Figure 2 | The effects of the homocysteinylation of albumin on
warfarin (a), salicylic acid (SA, b), and diazepam binding (c) are
shown. Each point represents the mean (s.e.) of three different
experiments performed on different days and with different albumin
preparations. The effect of diazepam binding (c) of homocysteiny-
lated albumin with respect to control albumin is considered
extremely significant with the two-way analysis of variance test
(Po0.0001).
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At this point, we thought of analyzing the function of an
altered protein, that is, a protein subject to in vitro
homocysteinylation, according to a standard protocol. It is
known that, in uremia, albumin-binding capacity is re-
duced.27 The method utilized to study albumin function is
based on the fact that binding of various ligands to albumin
induces conformational changes with consequent quenching
of the intrinsic fluorescence of the tryptophan residue,
yielding different curves with various concentrations of the
tested compound.28 The three tested compounds, warfarin,
SA and diazepam, bind to different binding sites of albumin,
considered to be the major ones of importance in the
molecule. For diazepam, the curve deriving from homo-
cysteinylated albumin was significantly different from that of
control albumin, in that the percentage of quenching of
fluorescence was reduced. This indicates that, in the whole
range of concentrations relative to diazepam, homocysteiny-
lated albumin binds less diazepam, because quenching of
fluorescence by the diazepam molecule is reduced with
respect to control. In this respect, it has been recently
reported that Lys525 is the predominant site in human serum
albumin for N-homocysteinylation both in vitro and in
vivo.16 It also has to be considered that Lys525 is included in
the domain IIIB of human serum albumin, which is the
major benzodiazepine-binding site.29 Thus, the reduced
diazepam binding of homocysteinylated albumin presented
in this paper is satisfactorily explained by these observations.
Folate therapy significantly lowered tHcy levels in our
patient population, which was not supplemented with
vitamins in the previous 2 months (and in the majority of
cases, was not supplemented at all during the whole course of
the disease). tHcy levels were reduced, but did not reach
normal levels as discussed previously. As a matter of fact, they
remained in the moderate range (16–30 mM).
Protein-N-Hcy was significantly reduced and in fact
reached almost normal levels, that is, levels statistically not
different from those of control subjects. Therefore, this kind
of protein modification can be reversed in these patients.
As for protein-S-Hcy, the levels were significantly different
from the levels before therapy, in that they were significantly
reduced. However, after therapy, the levels were still higher
than normal controls.
These data suggest that the two types of homocysteinyla-
tion follow different dynamics in vivo, as mentioned
previously. In addition, 2 months of folate therapy represent
a longer time span with respect to the lifetime in circulation
of albumin (20 days). Therefore, other plasma proteins with a
longer half-time are probably involved in protein-S-homo-
cysteinylation, at least in uremia. However, taking every
element into consideration, our findings indicate that folate
therapy has the potential to reduce protein homocysteinyla-
tion levels.
In conclusion, this work shows that one of the mediators
of Hcy toxicity, protein homocysteinylation, is present in
uremic patients on hemodialysis, and that this modification
is influenced by folate treatment. This finding has functional
consequences; in fact, albumin subject to homocysteinylation
is altered, and it shows a reduced binding to diazepam, a
ligand to one of the main binding sites of albumin.
MATERIALS AND METHODS
Patients and treatment
Controls were volunteer healthy subjects recruited among hospital
staff (n¼ 14, mean age 53 years, age range 29–59 years). End-stage
renal disease patients were selected (n¼ 28, mean age 63 years, age
range 39–69 years), provided that they were not affected by systemic
diseases such as lupus erythematosus, etc. Patients were on regular
bicarbonate hemodialysis treatment for at least 6 months and were
clinically stable. Patients did not consume any folate vitamins, for at
least 2 months, or phosphodiesterase inhibitors.30 Diazepam,
warfarin and SA were not part of their therapeutic regimens. In
addition, patient anemia was controlled with erythropoietin and
iron therapy, as needed. Most patients followed various antihyper-
tensive regimens, and were treated for secondary hyperparathyroid-
ism with sevelamer and calcitriol. Informed consent was obtained
from each patient, and the study was approved by our institution’s
Ethics Committee. In a group of 15 hyperhomocysteinemic dialysis
patients, not consuming folate vitamins for a period of time not less
than 2 months, methyltetrahydrofolate (Prefolic, Zambon, Italy) was
administered by the dialysis physician to ensure compliance, for 2
months at a dose of 15 mg after each dialysis, per os. Patients did not
report any unusual symptoms during the study period. It is worth
mentioning that patients were not selected on the basis of their
plasma Hcy levels, neither in the experiments designed to measure
plasma protein homocysteinylation, nor for those on the effects of
folate therapy. Patients were initially selected for their clinical
characteristics and therefore were not diabetic, etc. As for the second
study on the effects of folate therapy, patients belonging to the
previous group who were still eligible (e.g. who were not
transplanted or deceased), and who did not consume any folates
in the intervening time, were included.
Blood was drawn immediately before the dialysis session using
ethylenediaminetetraacetic acid (1 mg/ml of blood). Vitamin B6 was
measured by a radioenzymatic assay;31 folate and vitamin B12 were
measured with a radioligand binding assay, utilizing commercially
available kits.
Determination of Hcy concentration
Hcy concentration was determined according to the method of
Ubbink et al.,32 as modified by Perna et al.1 Hcy represents total,
protein-bound and non-protein-bound Hcy (tHcy).
Protein homocysteinylation
In order to measure the incorporation of Hcy into proteins bound:
(a) covalently to Cys residues (protein-S-Hcy) and (b) bound
through an amide bond to the e-amino group of lysine residues, and
to the terminal amino group (protein-N-Hcy), we developed the
following protocol. tri-n-butyl-phosphine in N,N,-dimethylforma-
mide (1:10, v/v), 90 ml, was added to 900 ml of the plasma (reduction
step). A non-reduced control sample was prepared with distilled
water, instead of tri-n-butyl-phosphine in N,N,-dimethylforma-
mide. The mixture was vortexed and incubated at 41C for 30 min. In
the reduction step, Hcy covalently bound to proteins through a
disulfide bridge to Cys residues, particularly at position 34 of
albumin, is released in the medium. In addition, Hcy is released
from the disulfide Hcy–Hcy, and from the mixed disulfide Hcy–Cys.
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Some free Hcy is also normally present in the blood. To remove this
released Hcy, and subsequently measure it, a gel filtration step with a
PD-10 Sephadex G-25 column (Amersham Bioscience, Uppsala,
Sweden) was performed, according to the manufacturer’s instruc-
tions. Samples (brought to a volume of 2.5 ml with distilled water)
were layered onto the gel filtration columns. During this separation
procedure, first a 3.5 ml volume was collected, which contained
plasma proteins freed from Hcy bound, through the disulfide
bridge. A 7.5 ml aliquot was then collected, after the addition of
distilled water, which contained free Hcy. The homodimer Hcy–Hcy
and the disulfide Hcy–Cys were also present in this elution volume.
To further clarify, the 7.5 ml non-reduced aliquot contains free
Hcy, which was already present in the plasma, plus Hcy–Hcy and
Hcy–Cys (A in Figure 3). The 7.5 ml reduced aliquot contained Hcy
released from the disulfide Hcy–Cys, and from the homodimer
Hcy–Hcy, Hcy bound to proteins through the disulfide bond, and
free Hcy (Aþ in Figure 3). Considering the non-reduced 3.5 ml
sample, this aliquot contained Hcy bound to proteins both through
the amide and the disulfide bond (B in Figure 3). The reduced 3.5 ml
sample contained, after the gel filtration passage, only Hcy bound to
proteins through the amide bond (Bþ in Figure 3).
Protein aliquots (B and Bþ ) were treated as follows:
(a) To 300ml of non-reduced aliquot (B), 30 ml of tri-n-butyl-
phosphine in N,N,-dimethylformamide was added, to release
Hcy bound to proteins through the disulfide bridge. After
incubation at 41C for 30 min, 300 ml of 10% trichloroacetic
acid (Sigma-Aldrich, St Louis, MI) was added in order to
precipitate the proteins, and the mixture was centrifuged at
10 000 g for 10 min. At this point, it was necessary to derivatize
released Hcy, that is, to make it fluorescent with a fluorophore,
represented by ammonium 7-fluorobenzo-2-oxa-1,3-diazole-
4-sulphonate. In all, 100 ml of the supernatant was mixed with
20ml of 1.55 M NaOH, 250 ml of 0.125 M borate buffer
containing 4 mM Na ethylenediaminetetraacetic acid, plus
100ml of ammonium 7-fluorobenzo-2-oxa-1,3-diazole-4-sul-
phonate, and incubated at 601C for 1 h. For HPLC separation
and fluorescence detection, a 20ml volume was utilized. This
aliquot (C in Figure 3) contained Hcy bound to proteins
through the disulfide bond, which was determined as
micromolar concentration.
(b) To 300 ml of the reduced aliquot (Bþ ), 30ml of tri-n-butyl-
phosphine was added, in order to reduce the free –SH groups,
which could auto-oxidize, and cannot be detected subse-
quently. The mixture was incubated at 41C for 30 min; at the
end of incubation, the derivatization step was performed. In
all, 60 ml of NaOH, 750ml of borate buffer and 300 ml of
ammonium 7-fluorobenzo-2-oxa-1,3-diazole-4-sulphonate
were added and incubated at 601C for 1 h. The sample was
brought to a final volume of 2.5 ml with distilled water and
separated by gel filtration, as reported above. The obtained
3.5 ml volume contained only proteins to which Hcy was
bound through an amide bond. At this point, a complete
chemical hydrolysis was performed, in order to release Hcy
bound to proteins through the amide bond, and subsequently
measure it. The mixture was hydrolyzed overnight in 6 N HCl
at 1141C in vacuum hydrolysis tubes using the Reacti-Therm
III Heating Module (Pierce, Rockford, IL). Samples were dried,
suspended in 500ml of distilled water and filtered with Millex
syringe filters (Millipore, Bedford, MA). This sample con-
tained Hcy previously bound to proteins through the amide
bond (Cþ in Figure 3). Twenty microliters were utilized for
HPLC chromatography, according to the conditions described
previously for plasma Hcy determination. Protein content was
analyzed with the Bradford method (BioRad, Hercules, CA).
Micromolar concentrations of Hcy, referred to 1 l of the
plasma, obtained with HPLC were also normalized per
milligram protein. A schematic depiction of the procedure
and the species obtained can be found in Figure 3.
Experiments were carried out to verify whether the HCl hydrolysis
treatment could interfere with the ammonium 7-fluorobenzo-
2-oxa-1,3-diazole-4-sulphonate bond to Hcy, and therefore with the
derivatization procedure. Hcy standard was reduced and derivatized.
Afterwards one standard aliquot was treated with water; another
standard was treated with HCl and subsequently hydrolyzed. A
control made with waterþ hydrolysis was also run. No difference
was found between concentrations of standards treated with or
without HCl (data not shown).
Precipitation 
with TCA
Hydrolysis
Sephadex G-25
Reduction
and derivatization
Sephadex G-25
Reduction −
fHcy
Hcy−Hcy
Hcy−Cys
fHcy
Hcy/Hcy
Hcy/Cys
Hcy-S/S-protein
Hcy-S−S-Protein
Hcy-NH-Protein Hcy-NH-Protein
Hcy−S/S−Protein Hcy-N/Protein
HPLC analysis
Reduction + 
A A+
B
C
B+
C+
Schematic procedure
Figure 3 | Schematic procedure. In this figure, the procedure used
for the detection of both Hcy bound to proteins through the amide
bond and through the disulfide bridge is schematized. On the
reader’s left, the initial reduction step was not performed
(Reduction ). On the reader’s right, all steps were preceded by
reduction (Reduction þ ). When the symbol ‘’ is used, it means that
Hcy is considered to be still bound; when the symbol ‘/’ is used, Hcy is
considered to be released from breaking that particular bond.
fHcy¼ free Hcy. In the reduction step, Hcy covalently bound to
proteins through a disulfide bridge to cysteine (Cys) residues is
released into the medium. In addition, Hcy is released from the
disulfide Hcy–Hcy, and from the mixed disulfide Hcy–Cys. Some free
Hcy is also normally present in blood. To remove this released Hcy,
and subsequently measure it, a gel filtration step was performed.
Several aliquots were obtained. The nonreduced nonprotein aliquot
contains free Hcy, which is already present in plasma, plus Hcy–Hcy
and Hcy–Cys, which pass through the column as well (A in the figure).
The reduced nonprotein aliquot contains Hcy released from the
disulfide Hcy–Cys, and from the homodimer Hcy–Hcy, Hcy previously
bound to proteins through the disulfide bond, and free Hcy (Aþ in
the figure). Considering the nonreduced protein sample, this aliquot
contains Hcy bound to proteins both through the amide and the
disulfide bond (B in the figure). The reduced protein sample contains
after the gel filtration passage, only Hcy bound to proteins through
the amide bond (Bþ in the figure). B was reduced and derivatized,
obtaining C. This aliquot contains Hcy bound to proteins through
the disulfide bond, which was analyzed and measured. Bþ was
first reduced, then derivatized, and finally hydrolyzed (Cþ in the
figure). Cþ contains Hcy previously bound to proteins through the
amide bond.
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Production of homocysteinylated albumin
Human albumin was purchased from ICN, Aurora, OH. Homo-
cysteinylated albumin was produced according to the protocol
published in Jakubowski.13 Human albumin (0.175 g/ml solution)
was incubated with (or without in control experiments) Hcy
thiolactone at a 5 mM final concentration, in a 0.1 M sodium
phosphate (pH 7.4)/2 mM ethylenediaminetetraacetic acid buffer,
and incubated overnight at 371C. Hcy thiolactone that was not
incorporated into proteins, and therefore did not react with
albumin, was eliminated by gel filtration. Homocysteinylated
albumin and control albumin were assayed as detailed in the
preceding paragraph for quantification of protein-bound Hcy, both
through the amide bond and the disulfide bond.
Binding experiments with homocysteinylated albumin
Quenching of the intrinsic tryptophan fluorescence of albumin
induced by binding with warfarin, diazepam and SA was monitored
by spectrofluorimetry, and utilized to study protein function, as
described by Parikh et al.28 Warfarin, diazepam and SA were used to
study the three main binding sites of albumin. The percentage
quenching, as defined by Parikh et al.,28 represents the percent
reduction in fluorescence, with respect to the fluorescence of protein
alone in the absence of the drug. Two preparations were considered,
a control one represented by human albumin, and one represented
by homocysteinylated albumin, which were both diluted with
phosphate-buffered saline to reach a final concentration of 2.02 mM.
The two preparations were mixed with stock solutions of warfarin,
diazepam and SA, to reach various final concentrations (warfarin:
1.15–166.50 mM; diazepam: 0.60–320.00 mM and SA: 0.05–10 000mM).
After 30 min, fluorescence was measured at an excitation of 280 nm,
an emission of 340 nm and a slit width 2.5–10.0 mm. The percentage
quenching was plotted against the total drug concentration.
Statistical analysis
Statistical analysis was performed employing Student’s unpaired or
paired t-test, as appropriate. Sample sizes were estimated to be
adequate, and able to detect differences with an 80% statistical
power.33 The formula reported by Dawson-Saunders and Trapp33
was utilized to estimate sample size, employing the mean and s.d. of
data pertaining to the first pilot experiments. The within-run
coefficient of variation for the method relative to the determination
of Hcy bound to proteins through the amide bond (protein-N-Hcy)
and through the disulfide bridge (protein-S-Hcy) was 4.13%, and
the between-run coefficient of variation was 4.78%. Recovery was
determined according to Uji et al.,7 and was found to be complete.
Both Pearson’s correlation, two-tailed, and linear regression were
performed for tHcy and protein-N-Hcy, and for tHcy and protein-
S-Hcy.
A two-way analysis of variance was performed to assess the
effects of treatment, in the case of the homocysteinylated albumin
experiments.33 All calculations were performed using the software
package GraphPad Prism, Version 4.0 for Macintosh (GraphPad
Software, San Diego, CA). All results are presented as the mean
(s.e.).
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